If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEland Oil & Gas Regulatory News (ELA)

  • There is currently no data for ELA

Opuama Operations Update

21 Mar 2018 07:00

RNS Number : 3696I
Eland Oil & Gas PLC
21 March 2018
 

 

21 March 2018

 

Eland Oil & Gas PLC

("Eland" or the "Company")

 

Opuama Operations Update

 

 

 

Eland Oil & Gas PLC (AIM: ELA), an oil & gas production and development company operating in West Africa with an initial focus on Nigeria, announces the following operations update on the Opuama field in licence OML 40.

 

Further to the Company's announcement on 13 February 2018, mechanical issues with the OES Teamwork Rig have continued intermittently. The principal issue has been a lack of consistent power from the rig's engines and consequently the Company, through its joint-venture subsidiary Elcrest Exploration and Production Nigeria Ltd ("Elcrest"), has paused drilling any further until back-up engines arrive at the well site. We are finalising discussions for the supply of back-up engines with a number of suppliers and the back-up equipment is expected on site in April 2018. Drilling has been suspended and completion and production from Opuama-9 is now expected also in April 2018 with Opuama 10 following immediately thereafter.

 

Production performance from Opuama field remains strong, with gross production from all four wells hitting record levels of 23,164 bbls of oil per day (bopd) in March 2018. Opuama-9 and -10 wells are each expected to initially add a further 4,000 - 6,000 bopd of gross oil production each once brought online, underpinning our production target of reaching 30,000 bopd from Opuama during H1 2018.

 

Current total production from Opuama in 2018 stands at 1,421,292 barrels of oil (Net to Elcrest: 639,581). Since the beginning of the year Elcrest has lifted a total of 498,622 barrels of crude from Forcados terminal for a value of $33,409,195. Reflecting an average realised price of $67.00 per barrel. Elcrest has a further parcel of 100,000 barrels programmed to be lifted and sold in the next 10 days.

 

 

George Maxwell, CEO of Eland, commented:

"Although any delay is frustrating it is not unexpected during a multi-well drilling campaign. I am very pleased with how our team and our partners have responded to the challenge and it should not mask the success of our ongoing drilling campaign which has increased gross production from 12,000 bopd to a record 23,164 boepd in under six months.

 

Through our increasing lifting volumes, all our stakeholders are starting to see the positive financial effects of our successful drilling campaign and resulting significant ramp-up in production."

 

For further information:

 

Eland Oil & Gas PLC (+44 (0)1224 737300)

www.elandoilandgas.com

George Maxwell, CEO

Ronald Bain, CFO

Finlay Thomson, IR

 

Canaccord Genuity Limited (+44 (0)20 7523 8000)

Henry Fitzgerald O'Connor / James Asensio

 

Panmure Gordon (UK) Limited (+44 (0)20 7886 2500)

Adam James / Atholl Tweedie

Tom Salvesen

 

Camarco (+44 (0) 203 757 4980)

Billy Clegg / Georgia Edmonds / Tom Huddart

 

In accordance with the guidelines of the AIM Market of the London Stock Exchange, Pieter van der Groen, a geologist and Eland's Chief Operating Officer, who has a geology degree from Auckland University, a Masters degree in Petroleum Geology from the University of Aberdeen and has over 25 years of relevant experience in the upstream oil and gas industry and who is a member of the Society of Petroleum Engineers and meets the criteria of qualified person under the AIM guidance note for mining and oil and gas companies, has reviewed and approved the technical information contained in this announcement.

 

Notes to editors:

Eland Oil & Gas is an AIM-listed independent oil and gas company focused on production and development in West Africa, particularly the highly prolific Niger Delta region of Nigeria.

Through its joint venture company Elcrest, Eland's core asset is OML 40 which is in the Northwest Niger Delta approximately 75km northwest of Warri and has an area of 498km². In addition, the Company has a 40% interest in the Ubima Field, onshore Niger Delta, in the northern part of Rivers State.

The OML 40 licence holds gross 2P reserves of 83.2 mmbbls, gross 2C contingent resources of 41.2 mmbbls and a best estimate of 254.5 mmbbls of gross unrisked prospective resources. The Ubima field holds gross 2P reserves of 2.4 mmbbls of oil and gross 2C resource estimates of 31.1 mmbbl.*

Net production figures relate to Elcrest Exploration and Production Nigeria Ltd ("Elcrest"), Eland's joint venture company. Production rates, when oil is exported via Forcados, are as measured at the Opuama PD meter, are subject to reconciliation and will differ from sales volumes.

*Netherland, Sewell & Associates Inc CPR report 31 June 2015

 The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
UPDSESEDSFASELD
Date   Source Headline
15th Nov 20062:50 pmRNSAnnual Report
25th Oct 20062:18 pmRNSBlocklisting Interim Review
25th Oct 20067:30 amBUSElan Reports Third Quarter 2006 Financial Results
24th Oct 20061:00 pmBUSTYSABRI(R) Maintained Remission in Patients with Moderate-to-Severe Crohn's Disease Treated for Longer Than Two Years According to Data Presented This Week
18th Oct 20068:42 amRNSHolding in Company
10th Oct 20067:00 amBUSNotice of Results
6th Oct 20062:07 pmBUSNew Pharmacoeconomic Data on TYSABRI(R) Demonstrate Significant Reduction in Steroid Use and Hospitalizations in Patients with Multiple Sclerosis
4th Oct 20061:00 pmBUSHealth Canada Grants Approval of TYSABRI(TM) (natalizumab) for the Treatment of Multiple Sclerosis Following Priority Review
29th Sep 20062:00 pmBUSNew Data Presented at ECTRIMS Congress Show TYSABRI(R) Has Sustained Effect on Relapse Rate in Multiple Sclerosis Patients Treated for up to Three Years
11th Sep 200611:57 amRNSFinancial Statements
9th Aug 20068:58 amRNSHolding in Company
2nd Aug 20065:26 pmRNSDirector/PDMR Shareholding
2nd Aug 200612:12 pmRNSHolding in Company
29th Jun 200612:32 pmRNSHolding in Company
21st Jun 200610:01 amRNSHolding in Company
15th Jun 20068:20 amRNSHolding in Company
7th Jun 20068:02 amRNSFurther re Appointment
1st Jun 200611:58 amRNSHolding in Company
25th May 20063:31 pmRNSHolding in Companies
25th May 200612:37 pmRNSHolding in Company
19th May 20065:51 pmRNSDirectors/PDMR Shareholding
19th May 200610:56 amRNSHolding in Company
17th May 200612:16 pmRNSHolding in Company
12th May 20061:45 pmRNSDirector/PDMR Shareholding
24th Apr 200611:36 amRNSHolding in Company
20th Apr 20064:44 pmRNSDocument Availability
19th Apr 20063:30 pmRNSHolding in Company
13th Apr 200612:51 pmRNSHolding in Company
13th Apr 200612:04 pmRNSAnnual Information Update
10th Apr 200612:42 pmRNSBrochure of Particulars
3rd Apr 20063:39 pmRNSBrochure of Particulars
13th Mar 200611:47 amRNSHoldings in Company
10th Mar 20063:24 pmRNSDirector/PDMR Shareholding
9th Mar 20067:30 amRNSRestoration of Listing
9th Mar 20067:01 amRNSOL Notice - Restoration
7th Mar 20061:00 pmRNSSuspension - Elan Corp Plc
7th Mar 20061:00 pmRNSOL Notice - Suspension
15th Feb 200610:15 amRNSBrochure of Particulars
10th Feb 20064:55 pmRNSDirector/PDMR Shareholding
9th Feb 20065:32 pmRNSDirector/PDMR Shareholding
9th Feb 20063:54 pmRNSHolding in Company
8th Feb 200610:56 amRNSDirector/PDMR Shareholding
3rd Feb 20069:58 amRNSDirector/PDMR Shareholding
25th Jan 200611:19 amRNSHolding in Company
9th Dec 20054:02 pmRNSDirector/PDMR Shareholding
17th Nov 20052:31 pmRNSRE:Director/PDMR Shareholding
1st Nov 20055:32 pmRNSDirector/PDMR Shareholding
22nd Sep 20059:43 amRNSRe: Brochure of Particulars
23rd Aug 20055:12 pmRNSDirector/PDMR Shareholding
21st Jun 200511:32 amRNSBrochure of Particulars

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.